WJMC - West Jefferson Medical Center

WJMC - West Jefferson Medical Center


Current Stroke Research at WJMC


RESPECT-ESUS Clinical Trial - Boehringer Ingelheim

Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetylsalicylic acid (100 mg oral q.d.) in patients with Embolic Stroke of Undetermined Source (RESPECT ESUS)

Purpose: To demonstrate that the efficacy of dabigatran etexilate (110 mg twice daily or 150 mg twice daily, with dosing according to age and renal function), is superior to ASA (100 mg once daily) for the prevention of stroke recurrence in patients with ESUS.

For more information visit: https://clinicaltrials.gov/ct2/show/NCT02239120

Return to Stroke Homepage



WJMC Pediatric Emergency